Abstract
Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely correlated with insulin resistance. Currently, the methods for clinical management of NAFLD patients mainly include removing causes, changing lifestyle and dietary structure, drug therapy and weight-loss surgery. This paper summarizes the occurrence and clinical management of NAFLD in patients with obesity, with the aim of formulating scientific clinical interventions for these patients and thus preventing the occurrence of NAFLD.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Korio G. Treatment of obesity with western medicine and traditional medicine: based on pubmed and science direct databases. Chin Med Cult 2019;2:99–104.10.4103/CMAC.CMAC_21_19Search in Google Scholar
2. Ludwig U, Holzner D, Denzer C, Greinert A, Haenle MM, et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord 2015;15:41–8.10.1186/s12902-015-0030-5Search in Google Scholar PubMed PubMed Central
3. Zhou YY, Zhou XD, Wu SJ. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun 2018;2:376–92.10.1002/hep4.1155Search in Google Scholar PubMed PubMed Central
4. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015;62:773–83.10.1002/hep.27869Search in Google Scholar PubMed PubMed Central
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.10.1002/hep.28431Search in Google Scholar PubMed
6. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr 2013;162:496–500.10.1016/j.jpeds.2012.08.043Search in Google Scholar PubMed PubMed Central
7. Wei Z, Lai W. Prevalence of nonalcoholic fatty liver disease in Asia. Chin J Hepatol 2013;21:801–4.Search in Google Scholar
8. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015;10:e0140908.10.1371/journal.pone.0140908Search in Google Scholar PubMed PubMed Central
9. Bonci E, Chiesa C, Versacci P, Anania C, Silvestri L, et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed Res Int 2015;2015:1–11.10.1155/2015/213737Search in Google Scholar PubMed PubMed Central
10. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. Mechanism of hepatic insulin resistance in on-alcoholic fatty liver disease. J Biol Chem 2004;279:32345–53.10.1074/jbc.M313478200Search in Google Scholar PubMed
11. Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, et al. Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance. Hepatology 2018;67:145–58.10.1002/hep.29465Search in Google Scholar PubMed
12. Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, et al. Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009;86:42–7.10.1016/j.eplepsyres.2009.04.004Search in Google Scholar PubMed
13. Hironori K, Guanliang C, Yinhua N, Tsuguhito O. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients 2017;9:387.10.3390/nu9040387Search in Google Scholar PubMed PubMed Central
14. Reitman ML, Gavrilova O. A-ZIP/F-1 mice lacking white fat: a model for understanding lipoatrophic diabetes. Int J Obes 2000;24:S11–4.10.1038/sj.ijo.0801493Search in Google Scholar PubMed
15. Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol 2015;63:164–73.10.1016/j.jhep.2015.02.019Search in Google Scholar PubMed
16. Kyoung-Jin O, Da L, Kim W, Beak H, Sang L, et al. Metabolic adaptation in obesity and type II diabetes: myokines, adipokines and hepatokines. Int J Mol Sci 2017;18:8.Search in Google Scholar
17. Martins AR, Nachbar RT, Gorjao R, Vinolo MA, Festuccia WT, et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis 2012;11:30.10.1186/1476-511X-11-30Search in Google Scholar PubMed PubMed Central
18. Hannah WN, Harrison SA. Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 2016;61:1365–74.10.1007/s10620-016-4153-ySearch in Google Scholar PubMed
19. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2010;50:1105–12.10.1002/hep.23129Search in Google Scholar PubMed
20. China consensus committee on overweight and obesity medical nutrition therapy. Expert consensus on medical nutrition therapy for overweight/obese in China (2016). Chin J Diabetes Mellitus 2016;8:525–40.Search in Google Scholar
21. Liu X, Fan J. The research progress and prospects on non-alcoholic fatty liver disease. J Mod Med Health 2017;33:641–4, 50.Search in Google Scholar
22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–57.10.1002/hep.29367Search in Google Scholar PubMed
23. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675–85.10.1056/NEJMoa0907929Search in Google Scholar PubMed PubMed Central
24. Liu Y, Zeng J, Fan J. Brief introduction of the Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017. J Prac Hepatol 2017;20:7–9.Search in Google Scholar
25. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–78.10.1053/j.gastro.2015.04.005Search in Google Scholar PubMed
26. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 2017;177:633–40.10.1001/jamainternmed.2016.9607Search in Google Scholar
27. Nan YM, Fu N, Li WC, Kong LL, Yuan XW, et al. An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017. Chin J Hepatol 2017;25:687–94.Search in Google Scholar
28. Zadik Z. Obesity and metformin. J Pediatr Endocrinol Metab 2012;25:1.10.1515/jpem-2012-0999Search in Google Scholar
29. Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, et al. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016;22:6100–13.10.3748/wjg.v22.i27.6100Search in Google Scholar
30. Lavine JE, Schwimmer JB, Natta ML, Molleston JP, Murray KF, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. J Am Med Assoc 2011;305:1659–68.10.1001/jama.2011.520Search in Google Scholar
31. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;15:1521–30.10.1016/j.cgh.2017.04.039Search in Google Scholar
32. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet (London, England) 2010;376:1916–22.10.1016/S0140-6736(10)61272-XSearch in Google Scholar
33. Mccrindle BW, Urbina EM, Dennison BA, Jacobson MS,Steinberger J, et al. Drug therapy of high risk lipid abnormalities in children and adolescents. Circulation 2007;115:1–20.10.1161/CIRCULATIONAHA.107.181946Search in Google Scholar PubMed
34. Terlemez S, Bozdemir E, Uçar SK, Kabaroğlu C, Habif S, et al. Insulin resistance in children with familial hyperlipidemia. J Pediatr Endocrinol Metab 2018;31:1349–54.10.1515/jpem-2018-0337Search in Google Scholar PubMed
35. Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res 2015;2015:1–8.10.1155/2015/706416Search in Google Scholar PubMed PubMed Central
36. Urakami T, Habu M, Okuno M, Suzuki J, Takahashi S, et al. Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. J Pediatr Endocrinol Metab 2014;28:327–31.10.1515/jpem-2014-0211Search in Google Scholar PubMed
37. Brito JP, Montori VM, Davis AM. Metabolic surgery in the treatment algorithm for type 2 diabetes. J Am Med Assoc 2017;317:635–6.10.1001/jama.2016.20563Search in Google Scholar PubMed PubMed Central
38. Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology 2017;65:1156–64.10.1002/hep.28958Search in Google Scholar PubMed
39. Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, et al. Bariatric surgery in patients with non-alcoholic fatty liver disease – from pathophysiology to clinical effects. World J Hepatol 2019;11:138–49.10.4254/wjh.v11.i2.138Search in Google Scholar PubMed PubMed Central
40. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014;260:898–9.10.1097/SLA.0000000000000945Search in Google Scholar PubMed
41. Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis 2016;12:127–31.10.1016/j.soard.2015.04.004Search in Google Scholar PubMed
©2020 Walter de Gruyter GmbH, Berlin/Boston
